Liraglutide 10MG

What it is: A synthetic analog of GLP-1 (glucagon-like peptide-1), a naturally occurring gut hormone. It’s a well-established, FDA-approved prescription drug — not a research chemical.

Mechanism: Mimics natural GLP-1 by binding GLP-1 receptors, which:

• Stimulates insulin release (glucose-dependent, so lower hypoglycemia risk)

• Suppresses glucagon secretion

• Slows gastric emptying

• Acts on appetite centers in the hypothalamus to reduce hunger

It’s modified with a fatty acid side chain that binds albumin, extending its half-life to ~13 hours (allowing once-daily dosing, vs. native GLP-1’s few minutes).

Approved medical uses:

• Type 2 diabetes (brand: Victoza) — improves blood sugar control

• Chronic weight management (brand: Saxenda) — approved for obesity/overweight with comorbidities

Evidence status: Strong — multiple large randomized controlled trials (e.g., LEADER trial) showing cardiovascular benefit in diabetics, plus robust weight-loss data. This is a mature, well-studied drug class.

Key considerations:

• Common side effects: nausea, GI upset, especially when starting/titrating dose

• Rare but serious: pancreatitis risk, contraindicated with personal/family history of medullary thyroid cancer

• Typically self-injected subcutaneously, dose titrated upward over weeks

• Note: 10mg would be an unusually described dose — Victoza/Saxenda are typically dosed in much smaller mg amounts (0.6–3.0mg) via pre-filled pens; “10mg” labeling usually signals a compounded or research-vendor product rather than the standard branded pharmaceutical